Skip to content

US · SLGL · BIOTECHNOLOGY

Sol-Gel Technologies Ltd. (SLGL) intrinsic value and stock valuation

$55.17as of 2026-11-21 · Mkt cap 287.67M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Sol-Gel Technologies Ltd. DCF and intrinsic value

InvestorsCraft values SLGL with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from SLGL’s statements →

Sol-Gel Technologies Ltd. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Ness Ziona, TA 7403650 sol-gel.com

How the business is doing

Fiscal 2014–2025, USD

Revenue
$19.4M+17.2% 5y CAGRd
20142025
Net income
-$-6.13M
20142025
Free cash flow
$280K
20142025
Total equity
$22.8M-14.8% 5y CAGRd
20142025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2014–2025, USD
20252024202320222021
Revenue$19.4M$11.5M$1.55M$3.88M$31.3M
Operating income-$-7.54M-$-12.01M-$-29.3M-$-16.24M$2.96M
Net income-$-6.13M-$-10.58M-$-27.24M-$-14.92M$3.22M
EPSd-$-2.2M-$-379.76K-$-1.01M-$-645.05K$136.6K
Operating cash flow$320K-$-13.89M-$-17.73M-$-9.48M-$-7.69M
Capital expenditure-$-50K-$0.00-$-130K-$-170K-$-140K
Free cash flow$280K-$-13.89M-$-17.86M-$-9.65M-$-7.83M
Total assets$29.9M$35.9M$45.3M$46.6M$69.2M
Total debt$990K$1.31M$1.65M$770K$1.59M
Net debt-$-10.04M-$-18.18M-$-5.86M-$-11.68M-$-18.49M
Total equity$22.8M$28.9M$38.6M$42.2M$55.6M
Cash and short-term investments$24M$23.9M$38M$33.6M$43.2M
Income statement
20252024202320222021
Revenue$19.4M$11.5M$1.55M$3.88M$31.3M
Cost of revenue$0.00$230K$340K$12.7M$20.4M
Gross profit$19.4M$11.3M-$-21.99M-$-8.8M$10.9M
Research and development expenses$22.8M$17.8M$23.5M$12.7M$20.4M
Selling, general and administrative expenses$4.18M$5.75M$7.37M$7.45M$8.45M
Other expenses-$-50K-$-230K-$-23.6M-$-12.68M-$-20.91M
Operating expenses$26.9M$23.3M$7.32M$7.45M$7.93M
Cost and expenses$26.9M-$-23.55M$30.9M$20.1M$28.3M
Interest income$1.41M$1.43M$2.07M$1.32M$260K
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$110K$230K$340K$560K$880K
Ebitda-$-7.43M-$-10.35M-$-28.96M-$-15.68M$3.84M
Operating income-$-7.54M-$-12.01M-$-29.3M-$-16.24M$2.96M
Total other income/expenses, net$1.41M$1.43M$2.07M$1.32M$260K
Income before tax-$-6.13M-$-10.58M-$-27.24M-$-14.92M$3.22M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-6.13M-$-10.58M-$-27.24M-$-14.92M$3.22M
Weighted average shares outstanding$2.79M$27.9M$27.1M$23.1M$23.1M
Weighted average diluted shares outstanding$2.79M$27.9M$27.1M$23.1M$23.6M
Balance sheet
20252024202320222021
Cash and short-term investments$24M$23.9M$38M$33.6M$43.2M
Net receivables$1.97M$3.6M$380K$7.92M$13.1M
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$27M$31.3M$41.2M$43.1M$57.1M
Property, plant and equipment, net$1.17M$1.63M$2.15M$1.54M$2.55M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$1.32M$2.31M$1.28M$1.29M$8.7M
Total non-current assets$2.95M$4.55M$4.12M$3.57M$12.1M
Total assets$29.9M$35.9M$45.3M$46.6M$69.2M
Accounts payable$730K$1.26M$150K$250K$770K
Short-term debt$490K$430K$450K$720K$780K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$6.17M$5.29M$4.52M$3.33M$11.7M
Long-term debt$500K$880K$1.21M$50K$810K
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$930K$1.71M$2.12M$1.09M$1.9M
Capital lease obligations$500K$1.31M$1.65M$770K$1.59M
Total liabilities$7.11M$7M$6.64M$4.42M$13.6M
Common stock$770K$770K$770K$640K$640K
Retained earnings-$-237.01M-$-230.88M-$-220.3M-$-193.06M-$-178.14M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$22.8M$28.9M$38.6M$42.2M$55.6M
Total investments$14.3M$6.75M$31.8M$22.5M$31.9M
Total debt$990K$1.31M$1.65M$770K$1.59M
Net debt-$-10.04M-$-18.18M-$-5.86M-$-11.68M-$-18.49M
Cash flow statement
20252024202320222021
Net income-$-6.13M-$-10.58M-$-27.24M-$-14.92M$3.22M
Depreciation and amortization$110K$230K$340K$560K$880K
Stock-based compensation$0.00$790K$1.86M$1.53M$690K
Change in working capital$6.19M-$-4.4M$7.67M$3.54M-$-12.44M
Accounts receivable$1.63M-$-4.2M$7.54M$12.6M-$-18.31M
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$820K$780K$1.47M-$-8.3M$5.62M
Net cash provided by operating activities$320K-$-13.89M-$-17.73M-$-9.48M-$-7.69M
Investments in property, plant and equipment-$-50K-$0.00-$-130K-$-170K-$-140K
Acquisitions, net$50K$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-8.58M$26.7M-$-9.74M$1.7M$19.9M
Common stock issued$10K$0.00$21.5M$10K$510K
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$10K$0.00$21.8M$10K$840K
Net change in cash-$-8.46M$12.8M-$-5.74M-$-7.64M$13M
Cash at end of period$11M$20.7M$7.86M$13.6M$21.2M
Operating cash flow$320K-$-13.89M-$-17.73M-$-9.48M-$-7.69M
Capital expenditure-$-50K-$0.00-$-130K-$-170K-$-140K
Free cash flow$280K-$-13.89M-$-17.86M-$-9.65M-$-7.83M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Sol-Gel Technologies Ltd.

        Sol-Gel Technologies Ltd., a pharmaceutical firm currently in its clinical development phase, specializes in the creation and market introduction of skin-applied medications. These products leverage the company's distinctive microencapsulation technology, with their primary development and commercialization activities centered in Israel. Sol-Gel's pipeline features several key candidates. Twyneo, an innovative, non-antibiotic topical cream designed for once-daily application, has successfully concluded Phase III trials for treating acne vulgaris. Similarly, Epsolay, another topical cream administered once a day, has also completed its Phase III studies, targeting papulopustular rosacea. Advancing through Phase I clinical trials is SGT-210, intended for palmoplantar keratoderma. Furthermore, the company is investigating Erlotinib, Tapinarof, and Roflumilast as potential treatments for psoriasis and various other medical conditions. Beyond its proprietary offerings, the company also engages in creating generic versions of topical dermatological medications. Sol-Gel Technologies maintains a strategic partnership with Perrigo. Established in 1997, the company maintains its headquarters in Ness Ziona, Israel.

        CEO
        Moshe Arkin
        Employees
        28
        Beta
        1.13

        Explore

        Frequently asked questions

        What is the intrinsic value of Sol-Gel Technologies Ltd. (SLGL)?

        InvestorsCraft does not currently publish an intrinsic value for SLGL. How the IC value is calculated.

        Is SLGL undervalued?

        InvestorsCraft does not publish an undervaluation signal for SLGL at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.